{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:46:27Z","timestamp":1788572787435,"version":"build-2803163510"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gouvernement du Canada | Canadian Institutes of Health Research","award":["PJT-156139"],"award-info":[{"award-number":["PJT-156139"]}]},{"name":"HHS | National Institutes of Health","award":["CA240301"],"award-info":[{"award-number":["CA240301"]}]},{"name":"FRQ | Fonds de Recherche du Qu\u00e9bec - Sant\u00e9"},{"name":"Gouvernement du Canada | Health Canada"},{"name":"Gouvernement du Canada | Canadian Institutes of Health Research"},{"name":"Gouvernement du Canada | Canadian Institutes of Health Research"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,9]]},"abstract":"<jats:p>Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer with an imperative need for new treatments. Immunotherapy has had marked success in some cancer types; however, clinical trials studying the efficacy of immune checkpoint inhibitors for the treatment of EOC benefited less than 15% of patients. Given that EOC develops from multiple tissues in the reproductive system and metastasizes widely throughout the peritoneal cavity, responses to immunotherapy are likely hindered by heterogeneous tumor microenvironments (TME) containing a variety of immune profiles. To fully characterize and compare syngeneic model systems that may reflect this diversity, we determined the immunogenicity of six ovarian tumor models in vivo, the T and myeloid profile of orthotopic tumors and the immune composition and cytokine profile of ascites, by single-cell RNA sequencing, flow cytometry, and IHC. The selected models reflect the different cellular origins of EOC (ovarian and fallopian tube epithelium) and harbor mutations relevant to human disease, including Tp53 mutation, PTEN suppression, and constitutive KRAS activation. ID8-p53\u2212\/\u2212 and ID8-C3 tumors were most highly infiltrated by T cells, whereas STOSE and MOE-PTEN\/KRAS tumors were primarily infiltrated by tumor-associated macrophages and were unique in MHC class I and II expression. MOE-PTEN\/KRAS tumors were capable of forming T-cell clusters. This panel of well-defined murine EOC models reflects some of the heterogeneity found in human disease and can serve as a valuable resource for studies that aim to test immunotherapies, explore the mechanisms of immune response to therapy, and guide selection of treatments for patient populations.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study highlights the main differences in the immunogenicity and immune composition found in six different models of orthotopic ovarian cancer as an essential tool for future preclinical investigations of cancer immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0017","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T09:28:04Z","timestamp":1653298084000},"page":"417-433","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool for Ovarian Cancer Immunotherapy Research"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5366-6047","authenticated-orcid":true,"given":"Galaxia M.","family":"Rodriguez","sequence":"first","affiliation":[{"name":"1Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada."},{"name":"2Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristianne J.C.","family":"Galpin","sequence":"additional","affiliation":[{"name":"1Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada."},{"name":"2Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7639-6724","authenticated-orcid":true,"given":"David P.","family":"Cook","sequence":"additional","affiliation":[{"name":"1Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada."},{"name":"2Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Yakubovich","sequence":"additional","affiliation":[{"name":"1Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada."},{"name":"2Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Maranda","sequence":"additional","affiliation":[{"name":"1Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada."},{"name":"2Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Macdonald","sequence":"additional","affiliation":[{"name":"1Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada."},{"name":"2Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Wilson-Sanchez","sequence":"additional","affiliation":[{"name":"1Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada."},{"name":"2Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6848-6666","authenticated-orcid":true,"given":"Anjali L.","family":"Thomas","sequence":"additional","affiliation":[{"name":"1Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada."},{"name":"2Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7271-6847","authenticated-orcid":true,"given":"Joanna E.","family":"Burdette","sequence":"additional","affiliation":[{"name":"3Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-7189","authenticated-orcid":true,"given":"Barbara C.","family":"Vanderhyden","sequence":"additional","affiliation":[{"name":"1Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada."},{"name":"2Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"2023031315103822700_","unstructured":"American Cancer Society. Cancer Facts & Figures; 2021 | American Cancer Society [Internet]. Available from: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2021.html"},{"key":"2023031315103822700_","volume-title":"Berek and Hacker's gynecologic oncology","author":"Berek","year":"2015","edition":"6th ed."},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ygyno.2016.07.105","article-title":"Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer","volume":"143","author":"Santoiemma","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"e80063","DOI":"10.1371\/journal.pone.0080063","article-title":"The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer","volume":"8","author":"Preston","year":"2013","journal-title":"PLoS One"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.1158\/1078-0432.CCR-08-0479","article-title":"Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer","volume":"14","author":"Callahan","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1272\/jnms.70.40","article-title":"Association of ovarian tumor epithelium coexpressing HLA-DR and CA-125 antigens with tumor infiltrating cytotoxic T lymphocytes","volume":"70","author":"Matsushita","year":"2003","journal-title":"J Nippon Med Sch"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3390\/cancers10080242","article-title":"The tumour microenvironment of epithelial ovarian cancer and its influence on response to immunotherapy","volume":"10","author":"Rodriguez","year":"2018","journal-title":"Cancers"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/cancers10080244","article-title":"Ovarian cancer immunotherapy: preclinical models and emerging therapeutics","volume":"10","author":"McCloskey","year":"2018","journal-title":"Cancers"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s10147-016-0959-z","article-title":"PD-1\/PD-L1 blockade in cancer treatment: perspectives and issues","volume":"21","author":"Hamanishi","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Medicine"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"e0155189","DOI":"10.1371\/journal.pone.0155189","article-title":"Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines","volume":"11","author":"Martin","year":"2016","journal-title":"PLoS One"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/01.cji.0000436722.46675.4a","article-title":"Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy","volume":"36","author":"Lechner","year":"2013","journal-title":"J Immunother"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1158\/2326-6066.CIR-16-0114","article-title":"Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery","volume":"5","author":"Mosely","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"e0206223","DOI":"10.1371\/journal.pone.0206223","article-title":"Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments","volume":"13","author":"Yu","year":"2018","journal-title":"PLoS One"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/carcin\/21.4.585","article-title":"Development of a syngeneic mouse model for events related to ovarian cancer","volume":"21","author":"Roby","year":"2000","journal-title":"Carcinogenesis"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-16-1272","article-title":"CRISPR\/Cas9-Mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma","volume":"76","author":"Walton","year":"2016","journal-title":"Cancer Res"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"16827","DOI":"10.1038\/s41598-017-17119-1","article-title":"CRISPR\/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity","volume":"7","author":"Walton","year":"2017","journal-title":"Sci Rep"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fonc.2014.00053","article-title":"A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population","volume":"4","author":"Mccloskey","year":"2014","journal-title":"Front Oncol"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"76881","DOI":"10.18632\/oncotarget.20173","article-title":"PAX2 maintains the differentiation of mouse oviductal epithelium and inhibits the transition to a stem cell-like state","volume":"8","author":"Alwosaibai","year":"2017","journal-title":"Oncotarget"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"20500","DOI":"10.18632\/oncotarget.3985","article-title":"Tumorigenesis and peritoneal colonization from fallopian tube epithelium","volume":"6","author":"Eddie","year":"2015","journal-title":"Oncotarget"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fonc.2015.00154","article-title":"Spontaneous transformation of murine oviductal epithelial cells: a model system to investigate the onset of fallopian-derived tumors","volume":"5","author":"Endsley","year":"2015","journal-title":"Front Oncol"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","article-title":"Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species","volume":"50","author":"Zilionis","year":"2019","journal-title":"Immunity"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"e0145342","DOI":"10.1371\/journal.pone.0145342","article-title":"Novel markers to delineate murine M1 and M2 macrophages","volume":"10","author":"Jablonski","year":"2015","journal-title":"Plos One"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"615655","DOI":"10.3389\/fgene.2021.615655","article-title":"Macrophage M2 co-expression factors correlate with the immune microenvironment and predict outcome of renal clear cell carcinoma","volume":"12","author":"Wang","year":"2021","journal-title":"Front Genet"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1158\/0008-5472.CAN-17-2465","article-title":"Expression of adipocyte\/macrophage fatty acid-binding protein in tumor-associated macrophages promotes breast cancer progression","volume":"78","author":"Hao","year":"2018","journal-title":"Cancer Res"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"e0150606","DOI":"10.1371\/journal.pone.0150606","article-title":"A protocol for the comprehensive flow cytometric analysis of immune cells in normal and inflamed murine non-lymphoid tissues","volume":"11","author":"Yu","year":"2016","journal-title":"Plos One"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"eaat7807","DOI":"10.1126\/scitranslmed.aat7807","article-title":"The hallmarks of successful anticancer immunotherapy","volume":"10","author":"Galluzzi","year":"2018","journal-title":"Sci Transl Med"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/imm.13114","article-title":"Cancer immune escape: MHC expression in primary tumours versus metastases","volume":"158","author":"Garrido","year":"2019","journal-title":"Immunology"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3389\/fimmu.2020.593058","article-title":"The Adipocyte and Adaptive Immunity","volume":"11","author":"Song","year":"2020","journal-title":"Front Immunol"},{"key":"2023031315103822700_","first-page":"139","article-title":"Carcinogen-induced bladder cancer in the FVB mouse strain is associated with glandular differentiation and increased Cd274\/Pdl-1 expression","volume":"7","author":"Amponsa","year":"2019","journal-title":"Am J Clin Exp Urol"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.parint.2011.07.001","article-title":"Cyst formation, increased anti-inflammatory cytokines and expression of chemokines support for Clonorchis sinensis infection in FVB mice","volume":"61","author":"Kim","year":"2012","journal-title":"Parasitol Int"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/01.shk.0000142249.08135.e9","article-title":"Innate immune response in Th1- and Th2-dominant mouse strains","volume":"22","author":"Watanabe","year":"2004","journal-title":"Shock"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/2159-8290.CD-20-0818","article-title":"Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy","volume":"11","author":"Iyer","year":"2021","journal-title":"Cancer Discov"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1158\/0008-5472.CAN-19-2558","article-title":"Murine oviductal high-grade serous carcinomas mirror the genomic alterations, gene expression profiles, and immune microenvironment of their human counterparts","volume":"80","author":"McCool","year":"2020","journal-title":"Cancer Res"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI123791","article-title":"Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers","volume":"129","author":"Malekzadeh","year":"2019","journal-title":"J Clin Invest"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1038\/s41467-018-05843-9","article-title":"Cas9 immunity creates challenges for CRISPR gene editing therapies","volume":"9","author":"Crudele","year":"2018","journal-title":"Nat Commun"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.xphs.2019.10.003","article-title":"Immunogenicity of Cas9 Protein","volume":"109","author":"Mehta","year":"2020","journal-title":"J Pharm Sci"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"e20210815","DOI":"10.1084\/jem.20210815","article-title":"Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts","volume":"219","author":"Kerdidani","year":"2022","journal-title":"J Exp Med"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/1078-0432.CCR-17-1090","article-title":"KRAS mutation and Consensus Molecular Subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal cancer","volume":"24","author":"Lal","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","article-title":"Pembrolizumab in patients with programmed death ligand 1\u2013positive advanced ovarian cancer: Analysis of KEYNOTE-028","volume":"152","author":"Varga","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","article-title":"Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma","volume":"46","author":"George","year":"2017","journal-title":"Immunity"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov"},{"key":"2023031315103822700_","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0017\/3151570\/crc-22-0017.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/6\/417\/3282309\/crc-22-0017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/6\/417\/3282309\/crc-22-0017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T21:11:43Z","timestamp":1700601103000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/6\/417\/704808\/The-Tumor-Immune-Profile-of-Murine-Ovarian-Cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,9]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0017","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.22544568","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544565","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550689","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544568.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550689.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544565.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]}}}